{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:37:51Z","timestamp":1790095071278,"version":"4.0.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"58","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The use of cannabis is not unfamiliar to many cancer patients, as there is a long history of its use for cancer pain and\/or pain, nausea, and cachexia induced by cancer treatment. To date, the US Food and Drug Administration has approved 2 cannabis-based pharmacotherapies for the treatment of cancer chemotherapy-associated adverse effects: dronabinol and nabilone. Over the proceeding decades, both research investigating and societal attitudes toward the potential utility of cannabinoids for a range of indications have progressed dramatically. The following monograph highlights recent preclinical research focusing on promising cannabinoid-based approaches for the treatment of the 2 most common adverse effects of cancer chemotherapy: chemotherapy-induced peripheral neuropathy and chemotherapy-induced nausea and vomiting. Both plant-derived and synthetic approaches are discussed, as is the potential relative safety and effectiveness of these approaches in relation to current treatment options, including opioid analgesics.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgab007","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T07:24:37Z","timestamp":1631085877000},"page":"78-85","source":"Crossref","is-referenced-by-count":26,"title":["Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects"],"prefix":"10.1093","volume":"2021","author":[{"given":"Sara Jane","family":"Ward","sequence":"first","affiliation":[{"name":"Department of Neural Sciences, Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron H","family":"Lichtman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Piomelli","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Neurobiology, Center for the Study of Cannabis, University of California, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Psychology and Neuroscience, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"issue":"2","key":"2022021611361104900_lgab007-B1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2010","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"2022021611361104900_lgab007-B2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"IJMS"},{"key":"2022021611361104900_lgab007-B3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fphar.2013.00156","article-title":"Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)","volume":"4","author":"Han","year":"2013","journal-title":"Front Pharmacol"},{"issue":"6","key":"2022021611361104900_lgab007-B4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","article-title":"Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort","volume":"89","author":"Shah","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2022021611361104900_lgab007-B5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0885-3924(00)00218-9","article-title":"Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review","volume":"20","author":"Collins","year":"2000","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"2022021611361104900_lgab007-B6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0149-2918(01)80058-8","article-title":"Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy","volume":"23","author":"Hemstreet","year":"2001","journal-title":"Clin Ther"},{"issue":"2","key":"2022021611361104900_lgab007-B7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"issue":"11","key":"2022021611361104900_lgab007-B8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies","volume":"44","author":"Wolf","year":"2008","journal-title":"Eur J Cancer"},{"key":"2022021611361104900_lgab007-B9","author":"Majithia","year":"15, 2016"},{"key":"2022021611361104900_lgab007-B10","doi-asserted-by":"crossref","first-page":"113154","DOI":"10.1016\/j.expneurol.2019.113154","article-title":"Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy","volume":"325","author":"Bruna","year":"2020","journal-title":"Exp Neurol"},{"issue":"4","key":"2022021611361104900_lgab007-B11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/cncr.20423","article-title":"Cancer patients\u2019 expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices","volume":"101","author":"Hofman","year":"2004","journal-title":"Cancer"},{"issue":"suppl 14","key":"2022021611361104900_lgab007-B12","first-page":"S259","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","volume":"23","author":"Adel","year":"2017","journal-title":"Am J Manag Care"},{"key":"2022021611361104900_lgab007-B13","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27(suppl 5","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"2022021611361104900_lgab007-B14","year":"2017"},{"issue":"3","key":"2022021611361104900_lgab007-B15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/clpt.1983.179","article-title":"Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women","volume":"34","author":"Wall","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2022021611361104900_lgab007-B16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.1980.181","article-title":"Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking","volume":"28","author":"Ohlsson","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2022021611361104900_lgab007-B17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-126-10-199705150-00008","article-title":"Medicinal applications of delta-9-tetrahydrocannabinol and marijuana","volume":"126","author":"Voth","year":"1997","journal-title":"Ann Intern Med"},{"issue":"2","key":"2022021611361104900_lgab007-B18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0885-3924(94)00117-4","article-title":"Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS","volume":"10","author":"Beal","year":"1995","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"2022021611361104900_lgab007-B19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0885-3924(97)00038-9","article-title":"Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia","volume":"14","author":"Beal","year":"1997","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"2022021611361104900_lgab007-B20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0091-3057(91)90385-F","article-title":"Recent clinical experience with dronabinol","volume":"40","author":"Plasse","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"2022021611361104900_lgab007-B21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/02791072.1998.10399689","article-title":"Abuse potential of dronabinol (Marinol)","volume":"30","author":"Calhoun","year":"1998","journal-title":"J Psychoactive Drugs"},{"issue":"7","key":"2022021611361104900_lgab007-B22","article-title":"Opioids for cancer pain\u2013an overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022021611361104900_lgab007-B23","volume-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","year":"2017"},{"issue":"2-3","key":"2022021611361104900_lgab007-B24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/j.1552-4604.1975.tb02348.x","article-title":"Analgesic effect of delta-9-tetrahydrocannabinol","volume":"15","author":"Noyes","year":"1975","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"2022021611361104900_lgab007-B25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","article-title":"Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial","volume":"68","author":"Abrams","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"2022021611361104900_lgab007-B26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/pm\/pnab050","article-title":"Nabiximols in chronic neuropathic pain: a meta-analysis of randomized placebo-controlled trials","volume":"22","author":"Dykukha","year":"2021","journal-title":"Pain Med"},{"key":"2022021611361104900_lgab007-B27","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/j.pain.0000000000002268","article-title":"Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies","volume":"162(suppl 1","author":"Finn","year":"2021","journal-title":"Pain"},{"issue":"7045","key":"2022021611361104900_lgab007-B28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/nature03658","article-title":"An endocannabinoid mechanism for stress-induced analgesia","volume":"435","author":"Hohmann","year":"2005","journal-title":"Nature"},{"issue":"9","key":"2022021611361104900_lgab007-B29","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/npp.2017.51","article-title":"Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis","volume":"42","author":"Nielsen","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"2022021611361104900_lgab007-B30","volume-title":"The Mysteries of Opium Revealed","author":"Jones","year":"1701"},{"issue":"5","key":"2022021611361104900_lgab007-B31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamapsychiatry.2019.4170","article-title":"All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis","volume":"77","author":"Larney","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2022021611361104900_lgab007-B32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"5090","key":"2022021611361104900_lgab007-B33","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"issue":"2","key":"2022021611361104900_lgab007-B34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/pr.112.006387","article-title":"Chemical probes of endocannabinoid metabolism","volume":"65","author":"Blankman","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"3","key":"2022021611361104900_lgab007-B35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1748-1716.1991.tb09232.x","article-title":"Tissue osmolality in intestinal villi of four mammals in vivo and in vitro","volume":"143","author":"Hallb\u00e4ck","year":"1991","journal-title":"Acta Physiol Scand"},{"issue":"1","key":"2022021611361104900_lgab007-B36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/npp.2015.166","article-title":"Neurobiological interactions between stress and the endocannabinoid system","volume":"41","author":"Morena","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"2022021611361104900_lgab007-B37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"9","key":"2022021611361104900_lgab007-B38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/nn1521","article-title":"Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus","volume":"8","author":"Makara","year":"2005","journal-title":"Nat Neurosci"},{"issue":"6","key":"2022021611361104900_lgab007-B39","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1523\/JNEUROSCI.5693-09.2010","article-title":"Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice","volume":"30","author":"Gao","year":"2010","journal-title":"J Neurosci"},{"issue":"10","key":"2022021611361104900_lgab007-B40","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/bph.13469","article-title":"Diacylglycerol lipase \u03b2 inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain","volume":"173","author":"Wilkerson","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2022021611361104900_lgab007-B41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.117.245704","article-title":"Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy","volume":"366","author":"Curry","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"2022021611361104900_lgab007-B42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neuropharm.2017.02.020","article-title":"Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse","volume":"117","author":"Toma","year":"2017","journal-title":"Neuropharmacology"},{"issue":"6","key":"2022021611361104900_lgab007-B43","doi-asserted-by":"crossref","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"de Almeida","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"8","key":"2022021611361104900_lgab007-B44","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ptr.2401","article-title":"Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved","volume":"22","author":"Comelli","year":"2008","journal-title":"Phytother Res"},{"issue":"1-3","key":"2022021611361104900_lgab007-B45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","article-title":"The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain","volume":"556","author":"Costa","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2022021611361104900_lgab007-B46","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy","volume":"171","author":"Ward","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"17","key":"2022021611361104900_lgab007-B47","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of \u03949-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"21","key":"2022021611361104900_lgab007-B48","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.2174\/1381612822666160311115226","article-title":"Polypharmacological properties and therapeutic potential of \u03b2-caryophyllene: a dietary phytocannabinoid of pharmaceutical promise","volume":"22","author":"Sharma","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"26","key":"2022021611361104900_lgab007-B49","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1073\/pnas.0803601105","article-title":"Beta-caryophyllene is a dietary cannabinoid","volume":"105","author":"Gertsch","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2022021611361104900_lgab007-B50","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1111\/bph.15486","article-title":"Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS-13019 in mouse models of pain and reinforcement","volume":"178","author":"Foss","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2022021611361104900_lgab007-B51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fphar.2016.00221","article-title":"Cannabinoids as treatments for chemotherapy-induced nausea and vomiting","volume":"7","author":"Rock","year":"2016","journal-title":"Front Pharmacol"},{"key":"2022021611361104900_lgab007-B52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejphar.2013.09.070","article-title":"Conditioned taste avoidance versus conditioned gaping: rat models of nausea-induced behavior","volume":"722","author":"Parker","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2022021611361104900_lgab007-B53","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejphar.2013.09.068","article-title":"Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system","volume":"722","author":"Sharkey","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"2022021611361104900_lgab007-B54","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00213-014-3498-1","article-title":"A comparison of treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping","volume":"231","author":"Rock","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"2022021611361104900_lgab007-B55","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00221-014-3942-9","article-title":"Animal model of anticipatory nausea: with relevance to clinical applications","volume":"232","author":"Rock","year":"2014","journal-title":"Exp Brain Res"},{"issue":"18","key":"2022021611361104900_lgab007-B56","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1097\/00001756-199912160-00009","article-title":"Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea","volume":"10","author":"Limebeer","year":"1999","journal-title":"Neuroreport"},{"issue":"8","key":"2022021611361104900_lgab007-B57","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"issue":"8","key":"2022021611361104900_lgab007-B58","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, attenuates vomiting and nausea by indirectly activating 5-HT1A somatodendritic receptors in the dorsal raphe nucleus","volume":"165","author":"Rock","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"5","key":"2022021611361104900_lgab007-B59","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00001756-200204160-00006","article-title":"Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats","volume":"13","author":"Parker","year":"2002","journal-title":"Neuroreport"},{"issue":"3","key":"2022021611361104900_lgab007-B60","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00213-019-05428-4","article-title":"Effect of combined doses of \u03949-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in Sprague-Dawley rats","volume":"237","author":"Rock","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"2022021611361104900_lgab007-B61","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00213-020-05559-z","article-title":"Cannabidiol (CBD), cannabidiolic acid (CBDA) and CBDA methyl ester (HU580) maintain their anti-nausea effectiveness with chronic administration by a serotonin 1A receptor mechanism of action","volume":"237","author":"Rock","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"2022021611361104900_lgab007-B62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0014-2999(85)90099-8","article-title":"Presynaptic 5-HT autoreceptors on serotonergic cell bodies and\/or dendrites but not terminals are of the 5-HT1A subtype","volume":"113","author":"Verge","year":"1985","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2022021611361104900_lgab007-B63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00213-003-1571-2","article-title":"Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew)","volume":"171","author":"Parker","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"2022021611361104900_lgab007-B64","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0256-18.2018","article-title":"Nausea-induced 5-HT release in the interoceptive insular cortex and regulation by monoacylglycerol lipase (MAGL) inhibition and cannabidiol","volume":"5","author":"Limebeer","year":"2018","journal-title":"eNeuro"},{"issue":"2","key":"2022021611361104900_lgab007-B65","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-003-1739-9","article-title":"A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew)","volume":"174","author":"Kwiatkowska","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"2022021611361104900_lgab007-B66","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/bph.12043","article-title":"Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation","volume":"168","author":"Bolognini","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2022021611361104900_lgab007-B67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bph.12162","article-title":"Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea) in rats","volume":"69","author":"Rock","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2022021611361104900_lgab007-B68","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bph.14073","article-title":"Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats","volume":"175","author":"Pertwee","year":"2018","journal-title":"Br J Pharmacol"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2021\/58\/78\/42539283\/lgab007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2021\/58\/78\/42539283\/lgab007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T09:24:10Z","timestamp":1699435450000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2021\/58\/78\/6446185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":68,"journal-issue":{"issue":"58","published-online":{"date-parts":[[2021,11,27]]},"published-print":{"date-parts":[[2021,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgab007","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,11,27]]}}}